首页> 外国专利> humanized antibodies, method for inhibiting binding of interferon-i to receptor-1, for inhibiting an immune response, for treating an autoimmune disorder, for modifying serum crp levels, for serum neopterin levels and for modifying proliferation of b-cells, and chimeric antibody

humanized antibodies, method for inhibiting binding of interferon-i to receptor-1, for inhibiting an immune response, for treating an autoimmune disorder, for modifying serum crp levels, for serum neopterin levels and for modifying proliferation of b-cells, and chimeric antibody

机译:人源化抗体,抑制干扰素i与受体1结合,抑制免疫应答,治疗自身免疫性疾病,改变血清crp水平,改变血清新蝶呤水平和改变b细胞增殖的方法,以及嵌合抗体

摘要

"HUMANIZED ANTIBODIES, METHOD FOR INHIBITING INTERFERON-I CONNECTION-1 BINDING, FOR INHIBITION OF AN IMMUNE RESPONSE, TO TREAT AUTOIMMUN DISORDER, TO MODIFY SERP CRP LEVELS FOR NEOPTERINE MODIFYER LEOPHERIN B-CELL AND CHEMICAL ANTIBODY ". Humanized IFNAR-1-binding monoclonal antibodies, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising humanized antibodies and therapeutic and diagnostic methods for using humanized antibodies.
机译:“人源化抗体,用于抑制干扰素-I连接1的方法,用于抑制免疫反应,治疗自体免疫紊乱,改变SERP CRP水平以用于新蛋白修饰的卵磷脂B细胞和化学抗体。”公开了人源化结合IFNAR-1的单克隆抗体,以及相关的基于抗体的组合物和分子。还公开了包含人源化抗体的药物组合物以及使用人源化抗体的治疗和诊断方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号